686279-09-4 Usage
General Description
4,6-Dichloro-2-methyl-nicotinic acid ethyl ester is a chemical compound that is often used as an intermediate in the synthesis of pharmaceutical products, agrochemicals, and other fine chemicals. It is a derivative of nicotinic acid, which is known for its potential therapeutic properties. 4,6-Dichloro-2-methyl-nicotinic acid ethyl ester is a liquid at room temperature and is soluble in organic solvents. Its chemical structure consists of a nicotinic acid core with two chlorine atoms and a methyl group attached to it, as well as an ethyl ester functional group. 4,6-Dichloro-2-methyl-nicotinic acid ethyl ester is commonly used in research and development, but precautions should be taken in handling and storing it due to its potentially hazardous properties.
Check Digit Verification of cas no
The CAS Registry Mumber 686279-09-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,8,6,2,7 and 9 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 686279-09:
(8*6)+(7*8)+(6*6)+(5*2)+(4*7)+(3*9)+(2*0)+(1*9)=214
214 % 10 = 4
So 686279-09-4 is a valid CAS Registry Number.
InChI:InChI=1S/C9H9Cl2NO2/c1-3-14-9(13)8-5(2)12-7(11)4-6(8)10/h4H,3H2,1-2H3
686279-09-4Relevant articles and documents
Used for the prevention and treatment of cardiovascular diseases
-
Paragraph 0402-0405, (2016/10/08)
The invention relates to compounds that can be used for adjusting the expression of apolipoprotein A-I (ApoA-I) and usage of the compounds in treating and preventing cardiovascular diseases and related diseases, including the disorder related to cholesterol or lipids such as atherosclerosis.
TREATMENT OF DISEASES BY EPIGENETIC REGULATION
-
Paragraph 0451; 0465, (2013/11/05)
The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of cancer, including NUT midline carcinoma, Burkitt's Lymphoma, Acute Myelogenous Leukemia, and Multiple Myeloma; autoimmune or inflammatory diseases or conditions, and sepsis.
BICYCLIC INHIBITORS OF ALK
-
, (2012/08/07)
The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, wherein R1, X, Y, Z, A, B, G1, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.
